Effects of vitamin b6 therapy for sepsis patients with linezolid-associated cytopenias: a retrospective study

Jie Deng, Long-Xiang Su, Zhi-Xin Liang, Li-Ling Liang, Peng Yan, Yan-Hong Jia, Xin-Gang Zhang, Dan Feng, Li-Xin Xie, Jie Deng, Long-Xiang Su, Zhi-Xin Liang, Li-Ling Liang, Peng Yan, Yan-Hong Jia, Xin-Gang Zhang, Dan Feng, Li-Xin Xie

Abstract

Background: The common adverse effects of linezolid for treating septic patients with gram-positive cocci is anemia and thrombocytopenia, which limit its clinical application.

Objectives: We determined the effects of vitamin B6 adjunctive therapy on linezolid-associated cytopenias, and retrospectively studied 75 septic patients who received at least 7 days of linezolid treatment.

Methods: Patients were divided into a linezolid treatment group (LTG; n = 41) that received linezolid only and a combination treatment group (CTG; n = 34) that received both linezolid and vitamin B6. Each group was further subdivided into those with sepsis and those with severe sepsis. Each patient had red blood cell (RBC), hemoglobin (Hb), hematocrit (Hct), and platelet (PLT) measurements at baseline (day 0) and every other day for 2 weeks during treatment; these parameters were compared between the groups and assessed for time-dependent trends.

Results: For patients in the LTG, RBC, Hb, and Hct values showed statistically significant reductions over time, and these values were lower compared with the values in the CTG. The CTG also showed downward trends, except on the first day of treatment. The PLT count also decreased in both groups. Patients with severe sepsis had lower PLT counts in both treatment groups compared with the septic patients.

Conclusions: Septic patients who received a combination treatment of linezolid and vitamin B6 might show positive effects for linezolid-associated reductions in some hematologic parameters (RBC, Hb, and Hct). This combined treatment might also slow PLT reduction, which was more evident in patients with severe sepsis. ClinicalTrials.gov identifier: NCT01295801.

Keywords: linezolid; linezolid-associated cytopenias; sepsis; vitamin B6.

Figures

Figure 1
Figure 1
Trends in laboratory parameters with treatment time. (A) Red blood cell (RBC), (B) hemoglobin (Hb), (C) hematocrit (Hct), (D) platelet (PLT), (E) PLTs for septic patients, and (F) PLTs for severe septic patients. ⁎P < 0.05 compared with the linezolid treatment group before treatment. †P < 0.05 compared with the combined treatment group before treatment. VB6, vitamin B6.

References

    1. Fraimow H.S., Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit Care Clin. 2011;27:163–205.
    1. Lowy F.D. Staphylococcal infections. In: Fauci A.S., Braunwald E., Kasper D.L., editors. Harrison's Principles of Internal Medicine. 17th ed. McGraw-Hill; New York: 2008. pp. 872–881.
    1. Moellering R.C. Linezolid: the first oxazolidinone antimicrobial. Ann Internal Med. 2003;138:135–142.
    1. Birmingham M.C., Rayner C.R., Meagher A.K. Linezolid for the treatment of multidrug-resistant, gram-positive infection: experience from a compassionate-use program. Clin Infect Dis. 2003;36:159–168.
    1. Senneville E., Legout L., Valette M. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother. 2004;54:798–802.
    1. Spellberg B., Yoo T., Bayer A.S. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother. 2004;54:832–835.
    1. Bone R.C., Balk R.A., Cerra F.B. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–1655.
    1. Levy M.M., Fink M.P., Marshall J.C. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250–1256.
    1. Plachouras D., Giannitsioti E., Athanassia S. Effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis. 2006;43:e89–e91.
    1. Andreu Ballester J.C., Ballester F., González Sánchez A. Epidemiology of sepsis in the Valencian Community (Spain), 1995-2004. Infect Control Hosp Epidemiol. 2008;29:630–634.
    1. Cheng B., Xie G., Yao S. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. J Crit Care Med. 2007;35:2538–2546.
    1. Yanagihara K., Kaneko Y., Sawai T. Efficacy of linezolid against methicillin-resistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection. Antimicrob Agents Chemother. 2002;46:3288–3291.
    1. Brown-Elliott B.A., Crist C.J., Mann L.B. In vitro activity of linezolid against slowly growing nontuberculous mycobacteria. Antimicrob Agents Chemother. 2003;47:1726–1738.
    1. Behra-Miellet J., Calvet L., Dubreuil L. Activity of linezolid against anaerobic bacteria. Int J Antimicrob Agents. 2003;22:28–34.
    1. Youssf S., Hachem R., Chemaly R.F. The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer. J Antimicrob Chemother. 2008;61:421–424.
    1. Young L.S. Hematologic effects of linezolid versus vancomycin. Clin Infect Dis. 2004;38:1065–1066.
    1. Harris J.W. X-linked, pyridoxine-responsive sideroblanstic anemia. N Engl J Med. 1994;330:709–711.
    1. Dawson M.A., Davis A., Elliott P., Cole-Sinclair M. Linezolid-induced dyserythropoiesis: chloramphenicol toxicity revisited. Intern Med J. 2005;35:626–628.
    1. Berndtein W.B., Trotta R.F., Rector J.T. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother. 2003;37:517–520.
    1. George J.N., Aster R.H. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program. 2009:153–158.
    1. Chong B.H., Du X.P., Berndt M.C. Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinindine-dependent antibodies. 1991;l77:2190–2199.
    1. Hiraki Y., Tsuji Y., Matsumoto K. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin. Am J Med Sci. 2011;342:456–460.
    1. Stalker D.J., Jungbluth G.L., Hopkins N.K., Batts D.H. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother. 2003;51:1239–1246.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する